Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40; New Analgesic Products Make It Past US FDA
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Trelegy, already approved for COPD, will be targeted to the roughly one-third of asthmatics not controlled on maintenance therapy.
Regulators in the US have approved Gavreto for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo.
The latest drug development news and highlights from our US FDA Performance Tracker.